About MAVIE
MAVIE is a venture capital firm founded in 2016. It is primarily based out of Shanghai, China. It primarily invests in France based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Auto Tech. Overall, MAVIE portfolio has seen 3 IPOs and 6 acquisitions including key companies like Robocath, Verona Pharma and Astronics Corporation. MAVIE has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio IPOs
MAVIE's List of Top Investments
MAVIE has a portfolio of 21 companies. Their most notable investments include Robocath and Verona Pharma.Their portfolio spans across France, Israel, United States and 4 more locations. They have invested in Life Sciences, High Tech, Auto Tech and 7 other sectors. Here is the list of top investments by MAVIE:1. Robocath
Robocath developed surgical arms for physicians to conduct remote surgery for cardiovascular diseases. The surgical robot can be manipulated by the physician for minimally invasive procedures. Their R-One robot consists of two core elements, first, it provides a radiation protection screen that protects medical staff from x-rays and another is a robot and its articulated support arm.
Key facts about Robocath
- Founded Year: 2009
- Location: Rouen (France)
- Annual Revenue: €1M - €10M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $57.9M
- Employee Count: 59 as on May 31, 2026
- Investors: Sylvain Zimmer, Bpifrance and 18 Others
- Latest Funding Round: Series C, Apr 29, 2020, $*****
- Highlight: Acquired
Developer of drugs for the treatment of respiratory diseases. Its drug pipeline includes RPL-554 (Phase 2) for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma; VRP700 for cough which is available for out-licensing. It has also identified certain marine organisms, such as starfish, a natural source of novel anti-inflammatory polysaccharides (NAIPS) without anti-coagulant actions.
Key facts about Verona Pharma
- Founded Year: 2005
- Location: London (United Kingdom)
- Annual Revenue: $10M - $50M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $74.8M
- Employee Count: 169 as on May 31, 2026
- Investors: Access Industries, Foresite Capital and 20 Others
- Latest Funding Round: Post IPO, Jul 17, 2020, $*****
- Highlight: Acquired
Manufacturer of power, connectivity, lighting, interiors, test, and safety systems. The company provides solutions for aircraft power, data, and entertainment. It offers products such as antennas, lighting, passenger service units, and emergency systems. The company also provides design, kitting, certification, and retrofit services.
Key facts about Astronics Corporation
- Founded Year: 1968
- Location: East Aurora (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Employee Count: 2,014 as on May 31, 2026
- Investors: White Hat Capital Partners and MAVIE
- Latest Funding Round: Post IPO, Jul 12, 2011, $*****
- Highlight: Public
HighLife Medical is developing a transcatheter mitral valve replacement system for the treatment of patients suffering from mitral valve regurgitation. It consists of two components, a valve prosthesis, and a ring-shaped sub-annular implant (SAI). The valve self-centers and aligns itself upon delivery inside the SAI ring surrounding it.
Key facts about HighLife Medical
- Founded Year: 2010
- Location: Paris (France)
- Stage: Series B
- Total Funding till date: $50.8M
- Employee Count: 85 as on May 31, 2026
- Investors: Sectoral, Andera Partners and 7 Others
- Latest Funding Round: Series B, Dec 11, 2020, $*****
- Highlight: Editors' Pick
ASLAN Pharmaceuticals is an oncology-focused company developing a portfolio of targeted drugs, focusing on gastric, bile duct and breast cancers. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced compounds are ASLAN001 which is pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer, and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET receptor tyrosine kinases, being developed in gastric and breast cancer.
Key facts about ASLAN Pharmaceuticals
- Founded Year: 2010
- Location: Singapore (Singapore)
- Stage: Public
- Total Funding till date: $100M
- Employee Count: 51 - 200 as on Jul 01, 2024
- Investors: BVF Partners, Sagamore Investment Management and 15 Others
- Latest Funding Round: Post IPO, Mar 02, 2023, $*****
- Highlight: Public
IPOs and Publicly Listed companies in MAVIE's Portfolio
3 of MAVIE's portfolio companies have become public. ASLAN Pharmaceuticals got listed on the Frankfurt Stock Exchange (FRA), in Dec 2019 and Shangyu Jingxin Pharmaceuticals got listed on the Shenzhen Stock Exchange (SZSE).Here are MAVIE's portfolio companies that went public:
Filter this listCompany | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 06, 2019 | - | - | 1160 | |
Jul 15, 2004 | - | - | 3099 | |
Oct 01, 1984 | - | - | 4431 |
Acquired companies in MAVIE's Portfolio
6 companies from MAVIE's portfolio have been acquired. The most recent acquisition was Endospan in May 2026 by Artivion for $*****.Here are MAVIE's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 18, 2026 | - | - | 6606 | |
Apr 15, 2026 | - | - | 4628 | |
Jul 09, 2025 | - | - | 6336 | |
Nov 01, 2023 | - | - | 4072 | |
Dec 18, 2018 | - | - | 1887 |
Team profile of MAVIE
MAVIE has a team of 2 members located in China. MAVIE's team does not sit on the board of any company as of now.Recent News related to MAVIE
•
Robocath Secures 40 Million Euros Series C FinancingMedical Product Outsourcing•Jun 29, 2020•Robocath, MicroPort Orthopedics, MAVIE, Bionest Partners Finance and 1 other
